Genprex (NASDAQ:GNPX) released its earnings results on Tuesday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.03), Bloomberg Earnings reports.
GNPX stock remained flat at $$0.86 during mid-day trading on Wednesday. 6,772 shares of the company’s stock traded hands, compared to its average volume of 40,343. Genprex has a 52-week low of $0.64 and a 52-week high of $2.98. The firm has a market cap of $15.56 million, a PE ratio of -0.96 and a beta of 1.49. The business’s 50 day moving average is $1.07.
Several research firms have commented on GNPX. Noble Financial began coverage on shares of Genprex in a report on Monday, April 29th. They issued an “outperform” rating and a $5.00 target price on the stock. Zacks Investment Research raised shares of Genprex from a “sell” rating to a “hold” rating in a report on Tuesday, June 18th. Finally, ValuEngine raised shares of Genprex from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Genprex Company Profile
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Featured Story: What are Bollinger Bands?
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.